Baseline Characteristics of Patients in SEQUOIA-HCM: A Phase 3 Trial of Aficamten in Obstructive Hypertrophic Cardiomyopathy

医学 肥厚性心肌病 内科学 心脏病学 心室流出道梗阻 射血分数 安慰剂 心室流出道 酒精间隔消融 心力衰竭 梗阻性心肌病 病理 替代医学
作者
Martin S. Maron,Theodore P. Abraham,Caroline Coats,Iacopo Olivotto,Matthew M.Y. Lee,Michael Arad,Nuno Cardim,Changsheng Ma,Lubna Choudhury,Hans‐Dirk Düngen,Pablo García‐Pavía,Albert Hagège,Gregory D. Lewis,Michelle Michels,Artur Oręziak,Anjali Owens,Jacob Tfelt‐Hansen,Josef Veselka,Hugh Watkins,Stephen B. Heitner,Daniel Jacoby,Stuart Kupfer,Fady I. Malik,Lisa Meng,Amy Wohltman,Ahmad Masri
出处
期刊:Journal of Cardiac Failure [Elsevier BV]
卷期号:30: S3-S3
标识
DOI:10.1016/j.cardfail.2023.11.006
摘要

Background Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by myocardial hypercontractility with left ventricular outflow tract obstruction (LVOTO), reduced exercise capacity, and heart failure symptoms. Aficamten is a next-in-class cardiac myosin inhibitor with unique physicochemical properties that appear to safely and effectively reduce LVOTO and improve symptoms and cardiac biomarkers (REDWOOD-HCM; NCT04219826). SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction, Impact of Aficamten in HCM; NCT05186818) is the pivotal Phase 3 trial evaluating the safety and efficacy of aficamten in patients with symptomatic oHCM and objective evidence of reduced functional capacity. Herein we present the baseline characteristics of patients enrolled in SEQUOIA-HCM. Methods SEQUOIA-HCM is an international, multicenter, randomized, double-blind, placebo-controlled trial in patients with symptomatic (NYHA class II–III) oHCM (left ventricular ejection fraction [LVEF] ≥60%; left ventricular outflow tract gradient [LVOT-G] ≥30 mmHg at rest and ≥50 mmHg with Valsalva), and peak oxygen uptake (pVO2) ≤80% of age- and sex-predicted maximum. Patients were randomized (1:1) to either oral placebo or aficamten, with site-based echocardiographic guidance to achieve individualized daily doses of 5, 10, 15, or 20 mg. The primary efficacy outcome is change in pVO2 on exercise testing from baseline to Week 24. Results SEQUOIA-HCM has enrolled 282 patients. Available patient characteristics at baseline are shown in Table 1. The mean (SD) age was 59.1 (12.9) years, 40.8% were female, and 22% were non-white. Baseline New York Heart Association functional class was Class II for 203 patients (72%), Class III for 67 patients (23.8%), and Class IV for 1 patient (0.4%). Just over half of the patients (172; 61%) were treated with beta-blockers. The mean baseline pVO2 was 18.5 (SD 4.5) mL/kg/min or 57.2% of predicted maximum, and the mean Kansas City Cardiomyopathy Questionnaire Clinical Summary Score was 74.7 (SD 18.1). Geometric mean (Q1, Q3) high-sensitivity cardiac troponin I was 16.9 (7.7, 27.2) ng/L. At this time, LVEF, LVOT-G, and N-terminal pro–B-type natriuretic peptide remain blinded measures. Conclusion SEQUOIA-HCM has enrolled a diverse and representative oHCM population with baseline characteristics reflecting significant symptom burden. Results will provide guidance on the utility of aficamten, a next-in-class cardiac myosin inhibitor, in patients with symptomatic oHCM. Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by myocardial hypercontractility with left ventricular outflow tract obstruction (LVOTO), reduced exercise capacity, and heart failure symptoms. Aficamten is a next-in-class cardiac myosin inhibitor with unique physicochemical properties that appear to safely and effectively reduce LVOTO and improve symptoms and cardiac biomarkers (REDWOOD-HCM; NCT04219826). SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction, Impact of Aficamten in HCM; NCT05186818) is the pivotal Phase 3 trial evaluating the safety and efficacy of aficamten in patients with symptomatic oHCM and objective evidence of reduced functional capacity. Herein we present the baseline characteristics of patients enrolled in SEQUOIA-HCM. SEQUOIA-HCM is an international, multicenter, randomized, double-blind, placebo-controlled trial in patients with symptomatic (NYHA class II–III) oHCM (left ventricular ejection fraction [LVEF] ≥60%; left ventricular outflow tract gradient [LVOT-G] ≥30 mmHg at rest and ≥50 mmHg with Valsalva), and peak oxygen uptake (pVO2) ≤80% of age- and sex-predicted maximum. Patients were randomized (1:1) to either oral placebo or aficamten, with site-based echocardiographic guidance to achieve individualized daily doses of 5, 10, 15, or 20 mg. The primary efficacy outcome is change in pVO2 on exercise testing from baseline to Week 24. SEQUOIA-HCM has enrolled 282 patients. Available patient characteristics at baseline are shown in Table 1. The mean (SD) age was 59.1 (12.9) years, 40.8% were female, and 22% were non-white. Baseline New York Heart Association functional class was Class II for 203 patients (72%), Class III for 67 patients (23.8%), and Class IV for 1 patient (0.4%). Just over half of the patients (172; 61%) were treated with beta-blockers. The mean baseline pVO2 was 18.5 (SD 4.5) mL/kg/min or 57.2% of predicted maximum, and the mean Kansas City Cardiomyopathy Questionnaire Clinical Summary Score was 74.7 (SD 18.1). Geometric mean (Q1, Q3) high-sensitivity cardiac troponin I was 16.9 (7.7, 27.2) ng/L. At this time, LVEF, LVOT-G, and N-terminal pro–B-type natriuretic peptide remain blinded measures. SEQUOIA-HCM has enrolled a diverse and representative oHCM population with baseline characteristics reflecting significant symptom burden. Results will provide guidance on the utility of aficamten, a next-in-class cardiac myosin inhibitor, in patients with symptomatic oHCM.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
2秒前
2秒前
4秒前
bkagyin应助dd采纳,获得10
4秒前
SciGPT应助Seoyeong采纳,获得10
4秒前
wxy发布了新的文献求助10
5秒前
6秒前
imxiaobing发布了新的文献求助10
6秒前
XiaoMing完成签到,获得积分10
6秒前
Muhammad发布了新的文献求助10
7秒前
7秒前
8秒前
你看起来很好吃完成签到,获得积分10
8秒前
9秒前
10秒前
zyn完成签到,获得积分10
11秒前
嗯呐发布了新的文献求助10
11秒前
Chengcheng发布了新的文献求助30
11秒前
XiaoMing发布了新的文献求助10
12秒前
高大的冰双完成签到,获得积分10
13秒前
13秒前
tt完成签到,获得积分10
14秒前
wxy完成签到,获得积分10
14秒前
15秒前
zyn发布了新的文献求助10
15秒前
谈舒怡发布了新的文献求助10
15秒前
HXY完成签到,获得积分10
16秒前
Seoyeong完成签到,获得积分20
17秒前
17秒前
小向1993发布了新的文献求助10
17秒前
18秒前
wzc完成签到,获得积分20
19秒前
JY完成签到,获得积分10
21秒前
andrele发布了新的文献求助10
21秒前
量子星尘发布了新的文献求助10
22秒前
Akim应助科研通管家采纳,获得10
22秒前
思源应助科研通管家采纳,获得10
22秒前
22秒前
无花果应助科研通管家采纳,获得10
22秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Effective Learning and Mental Wellbeing 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976126
求助须知:如何正确求助?哪些是违规求助? 3520340
关于积分的说明 11202586
捐赠科研通 3256847
什么是DOI,文献DOI怎么找? 1798509
邀请新用户注册赠送积分活动 877645
科研通“疑难数据库(出版商)”最低求助积分说明 806516